ASCO (American Society of Clinical Oncology) 2022 Colon Cancer Overview: MOASC Spotlight
Today I presented three clinical trials at the American Society of Clinical Oncology (ASCO) annual meeting. The first one is neoadjuvant immunotherapy in locally advanced rectal cancer (colorectal cancer).
That data was presented by MSK Group and given neoadjuvant immunotherapy for six months, giving a hundred percent clinical complete response rate or response duration in locally advanced rectal cancer care (colorectal cancer) patients. They don’t need to do any traditional chemotherapy, radiation, or surgery. They will just observe for now.
DYNAMIC trial
The second topic is ctDNA MRD guidance in adjuvant therapy physicians. I presented two trials. One was the DYNAMIC trial, in which stage two patients were randomized between the ctDNA-guided group and a standard management group. The conclusion was that disease-free survival is very similar. This is a non-inferiority trial. The disease-free survivor is non-inferior among the group. But what is found is that a few adjuvant therapies were given in the ctDNA-guided group.
CIRCULATE-Japan Trial
And then the CIRCULATE-Japan trial showed. If the ctDNA was negative in stage three patients, whether given adjuvant therapy or survivor is very similar in colorectal cancer research, including endoscopic visualization.
PARADIGM trial
The third topic that I presented is about first-line regimen in metastatic colorectal cancer care (colorectal cancer or rectal cancer) research at this cancer center. The first try is a PARADIGM trial, which shows that FOLFOX plus anti-EGFR. Is better for our survivor over FOLFOX plus Anti-VEGF inhibitor in the first line RAS wild-type left-sided tumor.
CAIRO Trial
The second trial I presented was the CAIRO study. They enrolled the unresectable colorectal (cancer) liver METS with the RAS BRAF mutator and right-sided patients treated, and then it showed that intensifying the chemotherapy FOLFOX series plus BEV has better progression-free survival over doublet therapy. But will this help with serious adverse events in patients with gastrointestinal cancers?
The GI (gastrointestinal cancer) in cancer (colorectal cancer) has been in terms of advancement has been so than compared to lung cancer. I think that it’s been exciting to see Neoadjuvant immunotherapy in early-stage disease, how ctDNA has been evolving, and even the last part about really defining the first-line therapy we should use. I think those have been exciting, especially doctors of clinical oncology.
I guess the next step that we’re waiting for is KRAS G12C data. We now know that we must combine the anti-EGFR with the KRAS G12C inhibitor together. We should see that this is a new development in the coming up ESMO for these outcomes and standard treatment a cancer center.
May Cho, MD – ASCO 2022 Colon Cancer In-Depth Slides: MOASC Spotlight
https://oncologytube.com/video/41298
May cho, MD – Question and Answer MOASC Presentation
https://oncologytube.com/v/41306
May Cho, MD (Clinical Oncology)– About The Author, Credentials, and Affiliations
Medical oncologist at UCI Health specializing in the diagnosis and treatment of gastrointestinal cancers (colorectal cancer), Dr. May T. Cho, holds board certification in her clinical oncology field and has extensive experience in the field. She has spent a considerable amount of time working with UCI Health.